Zobrazeno 1 - 10
of 36
pro vyhledávání: '"John C. Brady"'
Autor:
Andrew B. Nixon, Herbert I. Hurwitz, Hope E. Uronis, Ivy Altomare, Anthony Amara, Wanda Honeycutt, Herbert Pang, Anuradha Bulusu, Christel Rushing, John C. Brady, Mark D. Starr, Yingmiao Liu
The change from baseline to C2D1 and C3D1 for each biomarker was determined across all patients. Biomarker change was statistically analyzed using Wilcoxon signed rank tests and the corresponding p-values, as well as the direction of change, are pres
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64a91554a913118e5b92d68e0664dcac
https://doi.org/10.1158/1535-7163.22500114
https://doi.org/10.1158/1535-7163.22500114
Autor:
Andrew B. Nixon, Federico Innocenti, Hanna K. Sanoff, Michael S. Lee, Dominic T. Moore, Anastasia Ivanova, Kouros Owzar, Chiara Cremolini, Alfredo Falcone, Richard M. Goldberg, Daniele Rossini, Federica Marmorino, Kelli Hammond, John C. Brady, Mark D. Starr, Ace J. Hatch, Alexander B. Sibley, Kirsten Bell Burdett, Jing Lyu, Yingmiao Liu
Regorafenib is a tyrosine kinase inhibitor approved by the FDA for the treatment of patients with chemotherapy refractory metastatic colorectal cancer (mCRC). Regorafenib inhibits signaling through multiple receptors associated with angiogenesis, met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cc13a6f6766962d7be65cf3e676a3ff
https://doi.org/10.1158/1535-7163.c.6542764
https://doi.org/10.1158/1535-7163.c.6542764
Autor:
Andrew B. Nixon, Herbert I. Hurwitz, Hope E. Uronis, Ivy Altomare, Anthony Amara, Wanda Honeycutt, Herbert Pang, Anuradha Bulusu, Christel Rushing, John C. Brady, Mark D. Starr, Yingmiao Liu
Hierarchical clustering analyses may identify potential patterns of marker expression and biologically relevant groupings. As an example, PDGF-AA and PDGF-BB are tightly clustered at baseline, indicating that if a patient had high PDGF-AA levels, PDG
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6696ecf50d6c99a5da1e47d3d1020479
https://doi.org/10.1158/1535-7163.22500117.v1
https://doi.org/10.1158/1535-7163.22500117.v1
Autor:
Andrew B. Nixon, Herbert I. Hurwitz, Hope E. Uronis, Ivy Altomare, Anthony Amara, Wanda Honeycutt, Herbert Pang, Anuradha Bulusu, Christel Rushing, John C. Brady, Mark D. Starr, Yingmiao Liu
A novel combination of bevacizumab and everolimus was evaluated in refractory colorectal cancer patients in a phase II trial. In this retrospective analysis, plasma samples from 49 patients were tested for over 40 biomarkers at baseline and after one
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::412df4f894599ab824a547151665fd43
https://doi.org/10.1158/1535-7163.c.6536361.v1
https://doi.org/10.1158/1535-7163.c.6536361.v1
Autor:
Andrew B. Nixon, Herbert I. Hurwitz, Charles P. Theuer, Delia Alvarez, Bonne Adams, Herbert Pang, Christel Rushing, John C. Brady, Mark D. Starr, Yingmiao Liu
Dendrograms
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::233c8fbdba70ae2c77643a74b4f2d0b8
https://doi.org/10.1158/1535-7163.22504483
https://doi.org/10.1158/1535-7163.22504483
Autor:
Andrew B. Nixon, Herbert I. Hurwitz, Charles P. Theuer, Delia Alvarez, Bonne Adams, Herbert Pang, Christel Rushing, John C. Brady, Mark D. Starr, Yingmiao Liu
Biomarkers change on treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ead731397389bb36378525d393c339f
https://doi.org/10.1158/1535-7163.22504477.v1
https://doi.org/10.1158/1535-7163.22504477.v1
Autor:
Andrew B. Nixon, Federico Innocenti, Hanna K. Sanoff, Michael S. Lee, Dominic T. Moore, Anastasia Ivanova, Kouros Owzar, Chiara Cremolini, Alfredo Falcone, Richard M. Goldberg, Daniele Rossini, Federica Marmorino, Kelli Hammond, John C. Brady, Mark D. Starr, Ace J. Hatch, Alexander B. Sibley, Kirsten Bell Burdett, Jing Lyu, Yingmiao Liu
Figure S1, consort diagram. Table S1, pts characteristics. Table S2, baseline levels. Table S3, prognostic markers. Table S4, adjusted prognostic markers. Table S5, early changes. Table S6, late changes at disease progression.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e03a78e049b3b467e3d8a40989bca42
https://doi.org/10.1158/1535-7163.22520767
https://doi.org/10.1158/1535-7163.22520767
Autor:
Andrew B. Nixon, Herbert I. Hurwitz, Charles P. Theuer, Delia Alvarez, Bonne Adams, Herbert Pang, Christel Rushing, John C. Brady, Mark D. Starr, Yingmiao Liu
TRC105 is an anti-endoglin antibody currently being tested in combination with VEGF inhibitors. In the phase Ib trial, 38 patients were treated with both TRC105 and bevacizumab (BEV), and improved clinical outcomes were observed, despite the fact tha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54cd0932593e57b9fd3d85d4a89a6db7
https://doi.org/10.1158/1535-7163.c.6537748.v1
https://doi.org/10.1158/1535-7163.c.6537748.v1
Autor:
Daniel J. George, Michael J. Morris, Eric J. Small, Himisha Beltran, Brian I. Rini, Phillip G. Febbo, Herbert I. Hurwitz, Bin Luo, Ivo Shterev, John C. Brady, Mark D. Starr, Yingmiao Liu, Susan Halabi, Andrew B. Nixon
Supplementary Data from Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ca3cf6936da380693046daffdb61d86
https://doi.org/10.1158/1078-0432.22484208.v1
https://doi.org/10.1158/1078-0432.22484208.v1
Autor:
Herbert I. Hurwitz, Kouros Owzar, Eileen M. O'Reilly, Jeffrey A. Meyerhardt, Federico Innocenti, Bert H. O'Neil, Heinz-Josef Lenz, Luis Baez-Diaz, Alan P. Venook, Donna Niedzwiecki, John C. Brady, Mark D. Starr, Flora Mulkey, Chen Jiang, Ace J. Hatch, Yingmiao Liu, Alexander B. Sibley, Andrew B. Nixon
Supplementary Table from Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48adb960f441cc51d88179e4293b09fb
https://doi.org/10.1158/1078-0432.22483455
https://doi.org/10.1158/1078-0432.22483455